Human Patents (Class 435/366)
  • Patent number: 10704043
    Abstract: Optimized inhibitory nucleic acids are provided. The nucleic acids have sequences which include an optimal inhibitory motif, such as a GGG. Related methods are also described.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: July 7, 2020
    Assignee: Exicure, Inc.
    Inventors: Weston Daniel, Scott Mix
  • Patent number: 10704025
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: July 7, 2020
    Assignee: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • Patent number: 10655098
    Abstract: The embodiments of the invention described herein relate to systems and methods for culturing and/or maintaining intestinal cells, tissues and/or organoids in vitro. The cells, tissues and/or organoids cultured according to the methods and systems described herein can mimic or reproduce natural intestinal epithelial structures and behavior as well as support co-culture of intestinal microflora.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: May 19, 2020
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Donald E. Ingber, Hyun Jung Kim
  • Patent number: 10655100
    Abstract: The present invention relates to a method of inducing the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by CXCR2 stimulation, and more particularly, to a method of promoting the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by stimulating and activating the surface receptor CXCR2 of the embryoid bodies with the CXCR2-specific ligand GRO-?. The method of inducing the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by CXCR2 stimulation according to the present invention can increase the efficiency and utility of stem cells as a cell therapeutic agent, because it promotes the differentiation of stem cells into a specific germ layer serving as the origin of target cells, which is the first important step for inducing the differentiation of stem cells into specific cells.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 19, 2020
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Byung Soo Kim, Ji-Hye Jung, Yong Park
  • Patent number: 10655101
    Abstract: Methods of preparing ovarian tissue for primordial follicle growth are presented comprising the steps: providing an ovarian tissue sample comprising cortical tissue and stromal tissue; removing damaged tissue from the ovarian tissue sample where present; removing excess stromal tissue from the ovarian tissue sample where present; and then mechanically stretching the ovarian tissue sample along at least one dimension of the ovarian tissue sample, such that the size of the ovarian tissue sample along the at least one dimension is increased by at least 10%. Methods of growing viable oocyte in vitro, and methods of preparing individual ovarian follicles for growth are also presented.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: May 19, 2020
    Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    Inventors: Evelyn Elizabeth Telfer, Marie McLaughlin
  • Patent number: 10633541
    Abstract: A composition for sealing defects in structural materials such as roads or paved surfaces, the composition preferably comprising one or more shape memory polymer (SMP) components capable of responding to increased temperature by decreasing in volume. Smart SMP-based sealants of the invention serve to avoid adhesion failure between a sealant and the repaired structure when the repaired structure is subjected to varied temperatures that cause thermal expansion and contraction.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: April 28, 2020
    Assignee: Board of Supervisors of Louisiana State University Agriculture And Mechanical College
    Inventor: Guoqiang Li
  • Patent number: 10620109
    Abstract: The present invention aims to provide a method of sorting a skeletal muscle progenitor cell from a cell population containing the skeletal muscle progenitor cell. The above-mentioned problem is solved by providing a step of introducing miRNA-responsive mRNA into a cell population. The miRNA-responsive mRNA contains (i) a nucleic acid having a sequence specifically recognized by miRNA specifically expressed in a skeletal muscle progenitor cell, and (ii) a nucleic acid containing a sequence encoding a marker protein.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: April 14, 2020
    Assignee: KYOTO UNIVERSITY
    Inventors: Hirohide Saito, Seiya Takahashi, Hidetoshi Sakurai, Takahiko Sato, Satoru Takayama
  • Patent number: 10604739
    Abstract: Methods and composition for the production of cardiomyocytes from differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including differentiating pluripotent stem cells in a large volume of suspension culture in the presence of ROCK inhibitors are described. In further aspects, methods for differentiation of stem cells into cardiomyocytes that overcome variability between different stem cell clones and different batch of culture medium are provided.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 31, 2020
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Casey Stankewicz, Matt Riley, Nathaniel Beardsley, Wen Bo Wang, Peter Fuhrken, Steven Kattman
  • Patent number: 10583204
    Abstract: The present invention includes methods for transferring a multigenic phenotype to a cell by transfecting, preferably by phototransfection, and locally transfecting a cell or a cellular process with a laser while the cell is bathed in a fluid medium comprising two or more nucleic acids, thereby introducing the nucleic acid into the interior of the cell. Expression of the nucleic acids results in a multigenic phenotype in the tranfected cell.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: March 10, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: James Eberwine, Philip G. Haydon, Jai-Yoon Sul, Hajime Takano, Chia-Wen Kitty Wu, Fanyi Zeng
  • Patent number: 10577573
    Abstract: Embodiments described herein relate to an apparatus for positioning and securing an excised biological tissue specimen for imaging and analysis. In some embodiments, an apparatus includes a sample bag defining an inner volume configured to receive a biological tissue sample, and a sealing member coupled to the sample bag. An imaging window is disposed and configured to be placed in contact with at least a portion of the biological tissue sample, and a positioning member is coupled to the imaging window and is configured to be disposed against the sealing member to substantially seal the inner volume. The positioning member includes a vacuum port disposed and configured to be aligned with a vacuum source to withdraw air from the inner volume of the sample bag.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: March 3, 2020
    Assignee: PERIMETER MEDICAL IMAGING, INC.
    Inventors: Chao Fan, Elizabeth A. Munro, David Rempel, James Jackson
  • Patent number: 10577575
    Abstract: Embodiments for coating a bioreactor with a reagent are described. The embodiments may provide for changing flow rates, direction of flow, and/or bioreactor rotation to enhance the coating of the bioreactor prior to growing cells in the bioreactor.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: March 3, 2020
    Assignee: Terumo BCT, Inc.
    Inventor: Nathan D. Frank
  • Patent number: 10576105
    Abstract: Compositions of HLA-G+ MSC and methods of using them, including methods of transplanting compositions of HLA-G+ MSC into human recipients, are provided. Also provided are methods of preparing compositions of HLA-G+ MSC, including by treatment with DNA methylation inhibitors.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: March 3, 2020
    Assignee: ESCAPE THERAPEUTICS, INC.
    Inventor: Basil M. Hantash
  • Patent number: 10570362
    Abstract: A transfer device designed to extract an amorphous or semi-solid structure, tissue, or construct from supporting media while maintaining the spatial integrity/organizational architecture thereof. The transfer device can include a controller, an actuator assembly, a plunger, and a needle. The controller can move the transfer device and the plunger independently.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: February 25, 2020
    Assignee: DEKA Products Limited Partnership
    Inventors: Michael C. Tilley, Richard E. Andrews, Dane C. Fawkes
  • Patent number: 10519449
    Abstract: In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit ANGPT2 and/or PDGFB expression and are therefore useful for treating angiogenesis-associated diseases, such as cancer, AMD, and DME.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: December 31, 2019
    Assignee: OliX Pharmaceuticals, Inc.
    Inventors: Dong Ki Lee, Sun Woo Hong, Tae Yeon Lee, Sae-Lo-Oom Lee, Hanna Lee, Dayeon Yu, Ji Eom
  • Patent number: 10500306
    Abstract: The tissue construct with viable cells in an extracellular matrix made of fibrin is produced with a special method, in which a matrix material and cells are shaped into a hollow body, in particular a tubular hollow body, by means of a rotational casting method in a hollow mould (1), the method comprising the following steps: (a) introduction of cells of at least one cell type and/or a fibrinogen preparation into the rotating hollow mould (1) with the aid of an applicator (4), said applicator (4) being displaced along the rotational axis during the introduction and step (a) being performed one or more times; (b) continuation of the rotation process until the fibrinogen solidifies into a dimensionally stable matrix, obtaining a primarily solidified tissue construct; (c) removal of the tissue construct from the mould. The construct can also he obtained in a relatively short time from autologous materials.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: December 10, 2019
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Thomas Aper, Mathias Wilhelmi, Axel Haverich
  • Patent number: 10502738
    Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 10, 2019
    Assignee: AGEX THERAPEUTICS, INC.
    Inventor: Basil M. Hantash
  • Patent number: 10494609
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells and the products related to or resulting from such methods. In particular, the present invention provides an improved method for the formation of pancreatic hormone expressing cells and pancreatic hormone secreting cells. In addition, the present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer and the products related to or resulting from such methods. The present invention also provides methods to promote glucose-stimulated insulin secretion in insulin-producing cells derived from pluripotent stem cells.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: December 3, 2019
    Assignee: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • Patent number: 10494595
    Abstract: An object is to provide a method of manufacturing a vessel for embryoid body formation excellent in formability of an embryoid body and suitable for optical observation.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 3, 2019
    Assignee: NOF CORPORATION
    Inventors: Tomozumi Noda, Fumio Nakashima, Satoshi Yamada, Nobuyuki Sakamoto
  • Patent number: 10478525
    Abstract: A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such as a compression test, on a mechanical property of the bone body. When the test yields a desired result, the bone body is exposed to a second processing solution that is less acidic than the first, thus minimizing the exposure of the bone body to the harsh acidic conditions of the demineralization phase of the process.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: November 19, 2019
    Assignee: BACTERIN INTERNATIONAL, INC.
    Inventors: Nancy J. Shelby, Steven M. Scott, Benjamin P. Luchsinger, Gregory A. Juda, Kelly R. Kirker, Darrel L. Holmes, Jesus Hernandez
  • Patent number: 10473646
    Abstract: The invention relates to a method of in vitro culturing or expanding human or animal tissue (2, 2?). The method comprises: obtaining a sample of human or animal tissue; downsizing tissue (21, 21?) of the sample; generating an assembly by placing the downsized tissue on a scaffold or hydrogel (22, 22?); arranging the assembly inside a culture chamber of a 3D perfusion system (23, 23?); and perfusing the assembly in the 3D perfusion system for a predefined time (24, 24?). The method according to the invention allows for preparing and directly culturing in vitro fresh tissue specimens for a high efficient in vitro culturing using a perfused bioreactor system.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: November 12, 2019
    Assignees: UNIVERSITAETSSPITAL BASEL, CELLEC BIOTEK AG
    Inventors: Christian Hirt, Adam Papadimitropoulos, Giandomenica Iezzi, Volker Lorber, Manuele Giuseppe Muraro
  • Patent number: 10471097
    Abstract: The present invention relates to hyaluronic acid-rich node and duct system (HAR-NDS)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (NDSCs), which are adult stem cells having an ability to differentiate into HAR-NDS-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood cells. The present invention is capable of separating, from HAR-NDS, adult stem cells NDSCs and hematopoietic stem cells, which are not easy to obtain from bone marrow, peripheral blood and umbilical cord blood (cord blood), as an alternative source, and thus can be usefully used for treatment of brain diseases, neurological diseases, chronic infectious diseases, cancers, autoimmune diseases, organ regeneration treatments and various intractable diseases.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: November 12, 2019
    Assignee: Eutilex Co., Ltd.
    Inventor: Byoung Se Kwon
  • Patent number: 10428303
    Abstract: Improved methods of culturing embryos in media having amounts of lactate that have not previously been recognized as beneficial for embryo development. Also, compositions, devices and kits related to the same.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: October 1, 2019
    Assignee: FUJIFILM Irvine Scientific, Inc.
    Inventors: Rebecca Gilbert, Hsiao-Tzu Ni, Suh-Fon Hwan
  • Patent number: 10392600
    Abstract: The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. In accordance with the present invention, a selectable marker gene has been recombinantly targeted to the brachyury locus to allow the isolation and characterization of cell populations that comprise brachyury positive mesendoderm and mesoderm cells. The cell populations of the invention are useful for generating cells for cell replacement therapy.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: August 27, 2019
    Assignee: ICAHN School of Medicine at Mount Sinai
    Inventors: Gordon Keller, Valerie Kouskoff, Atsushi Kubo, Hans J. Fehling
  • Patent number: 10377989
    Abstract: The present invention provides methods of preparing aggregated pluripotent stem cell clusters for differentiation.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: August 13, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Benjamin Fryer, Daina Laniauskas, Marcia Blackmoore, Haiyun Wang, Kostadinka LiLova, Shelley Nelson, Elizabeth Rosocha
  • Patent number: 10370644
    Abstract: The present invention provides methods of preparing aggregated pluripotent stem cell clusters for differentiation. Specifically, the invention discloses methods of differentiating pluripotent cells into beta cell, cardiac cell and neuronal cell lineages using suspension clustering. The methods involve preparing the aggregated cell clusters followed by differentiation of these clusters.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: August 6, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Benjamin Fryer, Daina Laniauskas, Marcia Blackmoore, Haiyun Wang, Kostadinka Lilova, Shelley Nelson, Elizabeth Rosocha
  • Patent number: 10363341
    Abstract: The present invention relates to a tissue-engineered intervertebral disc (IVD) suitable for total disc replacement in a mammal and methods of fabrication. The IVD comprises a nucleus pulposus structure comprising a first population of living cells that secrete a hydrophilic protein and an annulus fibrosis structure surrounding and in contact with the nucleus pulposus structure, the annulus fibrosis structure comprising a second population of living cells and type I collagen. The collagen fibrils in the annulus fibrosis structure are circumferentially aligned around the nucleus pulposus region due to cell-mediated contraction in the annulus fibrosis structure. Also disclosed are methods of fabricating tissue-engineered intervertebral discs.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: July 30, 2019
    Assignee: Cornell University
    Inventors: Lawrence J. Bonassar, Roger Hartl, Robert D. Bowles, Harry H. Gebhard
  • Patent number: 10351827
    Abstract: There is provided a method of differentiating an induced pluripotent stem cell (iPSC) into a renal proximal tubular cell (PTC)-like cell. The method comprises culturing an undifferentiated iPSC in a renal epithelial cell culture medium in the presence of one or more extracellular matrix (ECM) molecules, bone morphogenic protein 2 (BMP2) and bone morphogenic protein 7 (BMP7), for a period of from about 8 to about 10 days, under conditions sufficient to induce differentiation of the iPSC into a PTC-like cell. A cell population of differentiated PTC-like cells is also provided, as well as uses and methods of use of the cell population.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: July 16, 2019
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Daniele Zink, Jackie Y. Ying
  • Patent number: 10336980
    Abstract: A portable apparatus useful for collection and processing of human biological material, such as adipose or cancellous bone material, to prepare a concentrated product (e.g., stromal vascular fraction). The apparatus has a container with a containment volume with a tissue retention volume and a filtrate volume separated by a filter and with a pellet well for collecting concentrate product in the form of a pellet phase from centrifuge processing. The pellet well is accessible only from above when the apparatus is in an access orientation. Collected pellet phase material may be removed from the pellet well by direct aspiration, without suspending the material in a suspension liquid within the container. Access ports may be configured for access only from above the container. The apparatus may include a tissue collector disposed in the disuse retention volume to engage and collect collagen or other stringy tissue.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: July 2, 2019
    Assignee: The GID Group, Inc.
    Inventors: William W. Cimino, Ramon Llull, Adam J. Katz
  • Patent number: 10337009
    Abstract: The invention provides a single-stranded nucleic acid molecule of (A) or (B) containing a TGF-?1 gene expression inhibitory sequence. The single-stranded nucleic acid molecule (A) consists of region (Xc), linker region (Lx) and region (X) from the 5?-side to the 3?-side, wherein linker region (Lx) has a non-nucleotide structure containing at least one of a pyrrolidine skeleton and a piperidine skeleton, and at least one of region (X) and region (Xc) contains the expression inhibitory sequence.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: July 2, 2019
    Assignee: BONAC CORPORATION
    Inventors: Takahiro Matsumoto, Hidekazu Toyofuku
  • Patent number: 10321704
    Abstract: The present application relates to propionic grain-based compositions comprising lactic acid-producing bacteria.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: June 18, 2019
    Assignee: Ganeden Biotech, Inc.
    Inventors: Sean Farmer, Andrew R. Lefkowitz, Michael Bush, David Maske
  • Patent number: 10287549
    Abstract: Provided is a muscle stem cell in vitro culture method. A muscle stem cell is cultivated in vitro by using a cell culture medium of a cell factor added with a blood cell or a conditioned medium of the blood cell. Also provided is a culture medium used in the muscle stem cell in vitro culture method and an application thereof.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 14, 2019
    Assignee: Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
    Inventors: Ping Hu, Xin Fu, Jun Xiao
  • Patent number: 10278993
    Abstract: A method for the treatment of acute stroke in a subject by administering to said subject an effective amount of a cell-based composition containing a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 7, 2019
    Assignee: Cytopeutics Sdn. Bhd.
    Inventors: Bernard Sze-Piaw Chin, Kong Yong Then, Soon Keng Cheong
  • Patent number: 10273459
    Abstract: The invention provides an automated system for producing induced pluripotent stem cells (iPSCs) from adult somatic cells. Further, the system is used for producing differentiated adult cells from stem cells. The invention system is useful for isolating somatic cells from tissue samples, producing iPSC lines from adult differentiated cells by reprogramming such cells, identifying the pluripotent reprogrammed adult cells among other cells, and expanding and screening the identified reprogrammed cells.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 30, 2019
    Assignee: New York Stem Cell Foundation
    Inventors: Scott Noggle, Kevin C. Eggan, Stephen Chang, Susan Solomon
  • Patent number: 10190097
    Abstract: The present invention provides a method of forming a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises steps of treating a human cell with a cell culture medium comprising fibromodulin (FMOD) for a period ranging from a day to a month, and changing the cell culture medium regularly until a FMOD reprogrammed (FreP) cell forms; wherein the FreP cell expresses NANOG and does not form teratoma, and wherein the human cell is a fibroblastic cell.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 29, 2019
    Assignee: The Regents of the University of California
    Inventors: B. Chia Soo, Kang Ting, Zhong Zheng
  • Patent number: 10179152
    Abstract: Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: January 15, 2019
    Assignee: Celularity, Inc.
    Inventors: Jodi P. Gurney, Xiaokui Zhang, Stacy Herb, Robert J. Hariri
  • Patent number: 10167449
    Abstract: An isolated human brown adipose tissue stem cell line. In one embodiment, the isolated human brown adipose tissue stem cell line expresses the markers CD9, SSEA4, CD44, CD90, CD166, CD73, but not CD14, CD34, CD45 or STRO-1. In another embodiment, the isolated human brown adipose tissue stem cell line expresses the genes UCP1, PPARGC1A, NRF1, FOXC2, CREB1, SIRT3, and WNT5A (REFX). In still another embodiment, the isolated human brown adipose tissue stem cell line is capable of differentiating into osteoblasts, chondrocytes, and adipocytes.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: January 1, 2019
    Assignee: BIORESTORATIVE THERAPIES, INC.
    Inventor: Francisco Javier Silva
  • Patent number: 10155927
    Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into cardiomyocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) into defined cardiomyocytes based on linked steps of chemically defined medium inductions.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: December 18, 2018
    Assignee: HOFFMANN-LA-ROCHE INC.
    Inventors: Mark Burcin, Sonja Schlicht
  • Patent number: 10150946
    Abstract: The present invention relates to a medium for storing, preserving, culturing, and/or differentiating stem cells. The medium employs a synthetic thermo-responsive copolymer, dispersed in an aqueous vehicle, which allows the medium to be readily “switched” between a non-gelatinous (fluid) form and a gelatinous form by simply adjusting temperature across the gelling temperature of the medium. As such, stem cells can be easily captured within a 3D gel matrix by simply mixing the stem cells with the non-gelatinous/fluid form of the medium and then gelling the medium by adjusting the temperature across the gelling temperature of the medium. The stem cells encapsulated within the gelatinous form of the medium may then be preserved for a significant time period before either using the stem cells directly within the medium (e.g. in therapy, or in culturing, differentiation, and such like), or after their extraction from the medium.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: December 11, 2018
    Assignee: The University of Sheffield
    Inventors: Irene Canton, Steven Peter Armes, Nicholas John Warren, Harry Moore, Giuseppe Battaglia, Denis Cecchin
  • Patent number: 10138463
    Abstract: The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: November 27, 2018
    Assignee: VIACYTE, INC.
    Inventor: Thomas C Schulz
  • Patent number: 10106773
    Abstract: The present invention relates to methods of isolating a substantially homogeneous population of pluripotent stem cells from adult neural crest tissue (e.g., periodontal ligament) as well as pharmaceutical compositions comprising such isolated pluripotent stem cells. Methods of inducing the isolated pluripotent stem cells into specific cell lineages, such as neurogenic and retinogenic lineages, are also described. The isolated pluripotent stem cells find use in various regenerative medicine applications and the treatment of degenerative diseases.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: October 23, 2018
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Herman S. Cheung, Daniel Pelaez, C-Y Charles Huang
  • Patent number: 10064893
    Abstract: Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: September 4, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Christopher H. Contag, Stephen H. Thorne
  • Patent number: 10047341
    Abstract: Provided herein are methods for the generation of functional keratinocyte stem cells that are differentiated directly from human ESCs/iPSCs in a chemically defined serum-free cell culture system, as well as cells derived therefrom and methods of use thereof. Also provided are methods for culturing primary keratinocytes.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: August 14, 2018
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Junying Yu, Ying Zhang, Lisa Harms
  • Patent number: 10035118
    Abstract: A system and method for isolating and separating lipoaspirate particles. The system includes a generally cylindrical container having a lid and a bottom wherein the container includes at least one input port positioned to permit a lipoaspirate fluid to enter the container above the bottom; and a source of a vacuum coupled to the container to provide a partial vacuum during use of the system.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: July 31, 2018
    Assignee: SpineSmith Partners, L.P.
    Inventors: Ted Sand, David Chau, Matthew R. DeWitt, Sujata Ghosh, Kevin Hao-Yu Lin
  • Patent number: 10030057
    Abstract: Described herein are novel compositions comprising multimodal TRAIL agents and cells engineered to express such multimodal TRAIL agents, including cells encapsulated in a scaffold or matrix, for use in the treatment of disorders such as cancer.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: July 24, 2018
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventor: Khalid Shah
  • Patent number: 10018630
    Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: July 10, 2018
    Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, PHARMALOGICALS RESEARCH PTE. LTD.
    Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
  • Patent number: 10018040
    Abstract: A technique facilitates detection and analysis of constituents, e.g. chemicals, which may be found in formation fluids and/or other types of fluids. The technique comprises intermittently introducing a first fluid and a second fluid into a channel in a manner which forms slugs of the first fluid separated by the second fluid. The intermittent fluids are flowed through the channel to create a mixing action which mixes the fluid in the slugs. The mixing increases the exchange, e.g. transfer, of the chemical constituent between the second fluid and the first fluid. The exchange aids in sensing an amount of the chemical or chemicals for analysis. In many applications, the intermittent introduction, mixing, and measuring can be performed in a subterranean environment.
    Type: Grant
    Filed: October 25, 2015
    Date of Patent: July 10, 2018
    Assignee: SCHLUMBERGER TECHNOLOGY CORPORATION
    Inventors: Farshid Mostowfi, Ronald E. G. van Hal, Shahnawaz Hossain Molla, Jane T. Lam, Amy Du, Neil William Bostrom, Michael Mallari Toribio
  • Patent number: 10010883
    Abstract: A deterministic lateral displacement array that includes a channel, within a substrate, having a first sidewall, a second sidewall, and a channel length. A condenser portion that includes an entry port and an exit port. A first array of pillars is disposed between the entry port and the exit port of the condenser portion along the channel length, the first array of pillars operative to drive a first material particle and a second material particle towards the first sidewall of the channel. A separator portion that includes an entry port and an exit port, and a second array of pillars disposed between the entry port and the exit port of the separator portion along the channel length, the pillars operative to drive the first material particle towards the second sidewall of the channel.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: July 3, 2018
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Huan Hu, Sung Cheol Kim, Joshua T. Smith, Benjamin H. Wunsch
  • Patent number: 10000740
    Abstract: This invention relates to the differentiation of pluripotent cells (PSCs) into foregut stem cells (FSCs) using a definitive endoderm induction medium comprising a TGFfi ligand, fibroblast growth factor (FGF), bone morphogenetic protein (BMP) and a PI3K inhibitor to differentiate the pluripotent cells into definitive endoderm cells and a foregut induction medium comprising a TGF? ligand to differentiate the definitive endoderm cells into foregut stem cells (FSCs). Methods of differentiation, populations of foregut stem cells, culture media and kits are provided.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: June 19, 2018
    Assignee: Cambridge Enterprise Limited
    Inventors: Ludovic Vallier, Nicholas Hannan
  • Patent number: 10000813
    Abstract: The invention relates to method and compositions for treating and diagnosing cancer, in particular ?-catenin related cancers. In general, the methods include administering RNAi constructs. The invention further relates to methods of identifying CTNNB1 related cancer therapeutics.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: June 19, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Mark J. Roth, Konrad Huppi
  • Patent number: 9994849
    Abstract: Provided is a method of separating senescent cells from a sample including the senescent cells, and a method of removing senescent cells from a sample or a subject including the senescent cells.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: June 12, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Byungju Kim, Sungjin Ryu, Sangchul Park